myo-Inositol trispyrophosphate hexa-triethylamine
Based on 1 Customer Validation
myo-Inositol trispyrophosphate (ITPP) hexa-triethylamine is a salt form of inositol triphosphate (ITPP). myo-Inositol trispyrophosphate hexa-triethylamine is a membrane-permeant hemoglobin allosteric regulator. myo-Inositol trispyrophosphate hexa-triethylamine enhances the oxygen release capacity of red blood cells by reducing the affinity of hemoglobin to oxygen. myo-Inositol trispyrophosphate hexa-triethylamine can be used in the study of cardiovascular disease and cancer.
For research use only. We do not sell to patients.
- Purity : 98.0%
- CAS No.: 851086-77-6
- Formula: C6H12O21P6.6C6H15N
- Molecular Weight:1213.13
-
Storage:
-20°C, protect from light, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
In Vitro
In Vivo
myo-Inositol trispyrophosphate (1.5 g/kg; intraperitoneal injection; twice a week for 4 weeks) has a protective effect in rat model of myocardial infarction[1].
myo-Inositol trispyrophosphate (1.5 g/kg; intravenous injection; once a week for 11 weeks) has antitumor activity in a rat model of pancreatic cancer[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male Wistar rats (280-320 g) with myocardial infarction[1]
-
Dosage:1.5 g/kg (Non-salt dose)
-
Administration:Intraperitoneal injection (i.p.); twice a week for 4 weeks
-
Result:Essentially halted the increase of LV dilation and significantly reduced impairment of LV ejection fraction, while it had no effect on sham-operated rats.
-
Animal Model:DSL-6A/C1 tumors treated immunocompetent male Lewis rats[2]
-
Dosage:1.5 g/kg (Non-salt dose)
-
Administration:Intravenous injection (i.v.); once a week for 11 weeks
-
Result:Significantly extended the survival time of rats.
Basically did not cause liver metastasis and primary tumor growth was restricted to 2 cm3.
Restored the pO2 pressure in tumors reducing hypoxia-inducible and proangiogenic factors.
Chemical Information
-
CAS No. 851086-77-6
-
Appearance Oil
-
Molecular Weight 1213.13
-
Formula C6H12O21P6.6C6H15N
-
Color Colorless to light yellow
-
SMILES
O=P1(O[C@]2([H])[C@@]3([H])[C@@](OP(O)(OP(O)(O3)=O)=O)([H])[C@]4([H])[C@@](OP(O)(OP(O)(O4)=O)=O)([H])[C@@]2([H])OP(O)(O1)=O)O.CCN(CC)CC.[6]
-
Synonyms
ITPP hexa-triethylamine
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
-20°C, protect from light, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)
Solvent & Solubility
In Vitro:
H2O : 125 mg/mL (103.04 mM; Need ultrasonic)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocols
-
Research Protocol for Cardiovascular Diseases
Cardiovascular disease can be modeled as maladaptive cardiac remodeling, where ischemic injury or pressure overload activates inflammatory signaling, fibroblast activation, extracellular-matrix deposition, cardiomyocyte hypertrophy, vascular remodeling, and progressive ventricular dysfunction. The TGF-β/SMAD axis is a central profibrotic pathway after myocardial injury and pressure overload, while innate immune and cytokine pathways regulate leukocyte recruitment, scar formation, and adverse remodeling. Key unresolved questions include which inflammatory signals are reparative versus harmful, when fibrosis is protective versus maladaptive, and whether pathway inhibition improves function without weakening necessary infarct healing or compensatory remodeling.
Purity & Documentation
-
Data Sheet (279 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Oknińska M, et al. Treatment of hypoxia-dependent cardiovascular diseases by myo-inositol trispyrophosphate (ITPP)-enhancement of oxygen delivery by red blood cells. J Cell Mol Med. 2020 Feb;24(3):2272-2283. [Content Brief]
[2]. Raykov Z, et al. Myo-inositol trispyrophosphate-mediated hypoxia reversion controls pancreatic cancer in rodents and enhances gemcitabine efficacy. Int J Cancer. 2014 Jun 1;134(11):2572-82. [Content Brief]
[3]. Fylaktakidou KC, et al. Inositol tripyrophosphate: a new membrane permeant allosteric effector of haemoglobin. Bioorg Med Chem Lett. 2005 Mar 15;15(6):1605-8. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O | 1 mM | 0.8243 mL | 4.1216 mL | 8.2431 mL | 20.6078 mL |
| 5 mM | 0.1649 mL | 0.8243 mL | 1.6486 mL | 4.1216 mL | |
| 10 mM | 0.0824 mL | 0.4122 mL | 0.8243 mL | 2.0608 mL | |
| 15 mM | 0.0550 mL | 0.2748 mL | 0.5495 mL | 1.3739 mL | |
| 20 mM | 0.0412 mL | 0.2061 mL | 0.4122 mL | 1.0304 mL | |
| 25 mM | 0.0330 mL | 0.1649 mL | 0.3297 mL | 0.8243 mL | |
| 30 mM | 0.0275 mL | 0.1374 mL | 0.2748 mL | 0.6869 mL | |
| 40 mM | 0.0206 mL | 0.1030 mL | 0.2061 mL | 0.5152 mL | |
| 50 mM | 0.0165 mL | 0.0824 mL | 0.1649 mL | 0.4122 mL | |
| 60 mM | 0.0137 mL | 0.0687 mL | 0.1374 mL | 0.3435 mL | |
| 80 mM | 0.0103 mL | 0.0515 mL | 0.1030 mL | 0.2576 mL | |
| 100 mM | 0.0082 mL | 0.0412 mL | 0.0824 mL | 0.2061 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
myo-Inositol trispyrophosphate hexa-triethylamine Related Classifications
HY-141510A Related Classifications
Powered by Bioz